European Journal of Dermatology
MENUCould anti-glycan antibodies be useful in dermatitis herpetiformis? Volume 29, numéro 3, May-June 2019
Illustrations
1 Department of Health Sciences, Section of Dermatology, University of Genoa, Genoa,
2 Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence,
3 Department of Health Sciences, Section of Statistics, University of Genoa, Genoa, Italy
- DOI : 10.1684/ejd.2019.3542
- Page(s) : 322-3
- Année de parution : 2019
Dermatitis herpetiformis (DH) is an autoimmune blistering disease associated with celiac disease (CD) [1]. Common serologic markers are anti-tissue transglutaminase (tTG), anti-epidermal TG (eTG), and anti-endomysium antibodies (EMA) [1, 2]. Anti-glycan antibodies (AGABs) comprise anti-Saccharomyces cerevisiae (ASCA), anti-chitobioside (ACCA), anti-laminaribioside (ALCA), and anti-mannobioside (AMCA) antibodies. AGABs reflect the interaction between the immune system and glycosylated cell wall components [...]